<p>隨着全球市場應對中東緊張局勢和能源市場波動的複雜性，美國主要股票指數表現出韌性，納斯達克綜合指數在混合的勞動數據和謹慎的地緣政治緩和背景下領先上漲。在這種環境中，識別高增長科技股需要尋找那些能夠對經濟條件變化表現出強大適應能力，並具備即使在更廣泛市場不確定性中也能蓬勃發展的創新能力的公司。</p>
<h3>全球十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州 TFC 光通信</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光電</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州東山精密製造</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 199 只股票的完整列表。</p>
<p>我們將從篩選結果中選取一些進行分析。</p>
<h2>Pharming Group (ENXTAM:PHARM)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Pharming Group N.V. 是一家生物製藥公司，專注於開發和商業化用於罕見疾病的蛋白質替代療法和精準醫療，業務覆蓋美國、歐洲及其他國際市場，市值為 10.1 億歐元。</p>
<p><strong>運營：</strong> Pharming Group 的收入主要來自其產品 Ruconest® 和 Joenja®，其中 Ruconest® 貢獻了 3.1792 億美元，Joenja® 貢獻了 5821 萬美元。該公司專注於罕見疾病的治療，服務於美國、歐洲及國際市場。</p>
<p>Pharming Group 在生物技術領域的最新進展凸顯了其在高增長科技行業的潛力，特別是在 CHMP 對 Joenja® 治療 APDS 的積極意見之後，為關鍵的 EC 決策奠定了基礎。這一進展與其財務回升相輔相成，預計 2025 年收入將從 2024 年的 2.97 億美元躍升至 3.76 億美元，淨利潤將從之前的虧損轉為 285 萬美元。研發工作依然強勁，這對維持創新和在罕見疾病治療市場的競爭力至關重要。這些因素共同突顯了 Pharming 在將科學進步轉化為商業可行解決方案方面的軌跡，增強了其在專業醫療市場的影響力。</p>
<ul>
<li>解鎖我們對 Pharming Group 股票分析的全面見解，請查看此健康報告。</li>
<li>通過我們的歷史報告獲取 Pharming Group 過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 ENXTAM:PHARM 收入和支出明細</p>
<h2>Ruijie Networks (SZSE:301165)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Ruijie Networks Co., Ltd. 從事網絡設備、網絡安全產品和雲桌面解決方案的設計、研發和銷售，業務覆蓋中國及國際市場，市值為 641.4 億人民幣。</p>
<p><strong>運營：</strong> Ruijie Networks 的收入主要來自網絡設備，貢獻了 125.2 億人民幣，其次是雲桌面解決方案和網絡安全產品，分別貢獻了 57.288 億人民幣和 49.372 億人民幣。</p>
<p>Ruijie Networks 展現出強勁的財務增長，過去一年收入從 117 億人民幣增長至 143 億人民幣，淨收入從 5.74 億人民幣上升至 6.96 億人民幣。這一表現得益於 36.7% 的顯著年盈利增長率，超過了通信行業平均水平 10% 以上。公司對創新的承諾在其戰略研發投資中得以體現，這對在快速發展的科技領域保持競爭優勢至關重要。預計未來三年，Ruijie Networks 的盈利將以約 36% 的年增長率增長，良好的市場機會將進一步推動其技術產品的擴展。</p>
<ul>
<li>在此深入瞭解 Ruijie Networks 的完整分析健康報告。</li>
<li>通過我們的詳細歷史表現報告評估 Ruijie Networks 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 SZSE:301165 盈利和收入增長</p>
<h2>Dexerials (TSE:4980)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dexerials Corporation，市值為 3625.3 億日元，專注於電子元件、粘合材料和光學材料的生產和銷售，主要在日本市場。</p>
<p><strong>運營：</strong> 該公司通過其光學材料和組件部門產生收入，貢獻了 466.2 億日元，電子材料和組件部門則帶來了 647.3 億日元。</p>
<p>在充滿挑戰的環境中，Dexerials Corporation 設法保持了 8.9% 的穩定收入增長。考慮到過去九個月淨收入從 233.6 億日元下降至 212.7 億日元，這一表現尤為顯著，反映出強大的運營韌性。公司的創新承諾在其研發支出中得以體現，這仍然是其戰略的關鍵方面，旨在促進技術進步並在持續演變的科技領域保持競爭力。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 Dexerials 的潛力。</li>
<li>查看 Dexerials 的過去業績報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4980 截至 2026 年 4 月的收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>點擊這裏訪問我們完整的 199 家全球高增長科技和人工智能股票索引。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
<h2>尋找新視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新警告信號或風險的提醒</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

核心標普美國增長 ETF - iShares

全球科技股指數 ETF - iShares

全美成長股指數 MSCI ETF - Vanguard

<p>隨着全球市場面臨中東緊張局勢和能源波動，美國股指，特別是納斯達克綜合指數，展現出韌性。高增長科技股備受關注，包括 Pharming Group、鋭捷網絡和 Dexerials，這些公司均表現出強勁的收入和盈利增長。Pharming 專注於罕見疾病治療，鋭捷在網絡解決方案方面表現出色，而 Dexerials 則專注於電子元件。在市場不確定性中，這些公司在各自領域展現出適應性和創新能力，為未來增長奠定了良好基礎</p>

<p>As global markets navigate the complexities of Middle East tensions and energy market volatility, major U.S. stock indexes have shown resilience, with the Nasdaq Composite leading gains amidst a backdrop of mixed labor data and tentative geopolitical de-escalation. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust adaptability to shifting economic conditions and possess innovative capabilities that can thrive even amid broader market uncertainties.</p>
<div class="lb-trans"><p>隨着全球市場應對中東緊張局勢和能源市場波動的複雜性，美國主要股票指數表現出韌性，納斯達克綜合指數在混合的勞動數據和謹慎的地緣政治緩和背景下領先上漲。在這種環境中，識別高增長科技股需要尋找那些能夠對經濟條件變化表現出強大適應能力，並具備即使在更廣泛市場不確定性中也能蓬勃發展的創新能力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州 TFC 光通信</td>
<td>43.76%</td>
<td>38.73%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光電</td>
<td>35.32%</td>
<td>37.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>21.22%</td>
<td>69.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>蘇州東山精密製造</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 199 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 199 只股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從篩選結果中選取一些進行分析。</p>
</div><h2>Pharming Group (ENXTAM:PHARM)</h2>
<div class="lb-trans"><h2>Pharming Group (ENXTAM:PHARM)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and other international markets, with a market cap of €1.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Pharming Group N.V. 是一家生物製藥公司，專注於開發和商業化用於罕見疾病的蛋白質替代療法和精準醫療，業務覆蓋美國、歐洲及其他國際市場，市值為 10.1 億歐元。</p>
</div><p><strong>Operations:</strong> Pharming Group generates revenue primarily from its products Ruconest® and Joenja®, with Ruconest® contributing $317.92 million and Joenja® $58.21 million. The company focuses on therapies for rare diseases, serving markets in the United States, Europe, and internationally.</p>
<div class="lb-trans"><p><strong>運營：</strong> Pharming Group 的收入主要來自其產品 Ruconest® 和 Joenja®，其中 Ruconest® 貢獻了 3.1792 億美元，Joenja® 貢獻了 5821 萬美元。該公司專注於罕見疾病的治療，服務於美國、歐洲及國際市場。</p>
</div><p>Pharming Group's recent strides in biotechnology underscore its potential within the high-growth tech sector, particularly following CHMP's positive opinion on Joenja® for treating APDS, setting the stage for a pivotal EC decision. This development complements their financial upturn, with 2025 witnessing a revenue jump to $376 million from $297 million in 2024 and a swing to net profits of $2.85 million from a prior loss. R&amp;D efforts remain robust, critical for sustaining innovation and market competitiveness in rare disease treatments. These factors collectively highlight Pharming's trajectory towards leveraging scientific advancements into commercially viable solutions, enhancing its footprint in specialized healthcare markets.</p>
<div class="lb-trans"><p>Pharming Group 在生物技術領域的最新進展凸顯了其在高增長科技行業的潛力，特別是在 CHMP 對 Joenja® 治療 APDS 的積極意見之後，為關鍵的 EC 決策奠定了基礎。這一進展與其財務回升相輔相成，預計 2025 年收入將從 2024 年的 2.97 億美元躍升至 3.76 億美元，淨利潤將從之前的虧損轉為 285 萬美元。研發工作依然強勁，這對維持創新和在罕見疾病治療市場的競爭力至關重要。這些因素共同突顯了 Pharming 在將科學進步轉化為商業可行解決方案方面的軌跡，增強了其在專業醫療市場的影響力。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Pharming Group stock in this health report.</li>
<li>Gain insights into Pharming Group's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Pharming Group 股票分析的全面見解，請查看此健康報告。</li>
<li>通過我們的歷史報告獲取 Pharming Group 過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>ENXTAM:PHARM Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 ENXTAM:PHARM 收入和支出明細</p>
</div><h2>Ruijie Networks (SZSE:301165)</h2>
<div class="lb-trans"><h2>Ruijie Networks (SZSE:301165)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Ruijie Networks Co., Ltd. is involved in the design, research, and sale of network equipment, network security products, and cloud desktop solutions both in China and internationally, with a market capitalization of CN¥64.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ruijie Networks Co., Ltd. 從事網絡設備、網絡安全產品和雲桌面解決方案的設計、研發和銷售，業務覆蓋中國及國際市場，市值為 641.4 億人民幣。</p>
</div><p><strong>Operations:</strong> Ruijie Networks generates revenue primarily from network equipment, contributing CN¥12.52 billion, followed by cloud desktop solutions and cyber security products at CN¥572.88 million and CN¥493.72 million, respectively.</p>
<div class="lb-trans"><p><strong>運營：</strong> Ruijie Networks 的收入主要來自網絡設備，貢獻了 125.2 億人民幣，其次是雲桌面解決方案和網絡安全產品，分別貢獻了 57.288 億人民幣和 49.372 億人民幣。</p>
</div><p>Ruijie Networks has demonstrated robust financial growth, with a notable increase in revenue from CNY 11.7 billion to CNY 14.3 billion and net income rising from CNY 574 million to CNY 696 million over the past year. This performance is underpinned by a significant annual earnings growth rate of 36.7%, outpacing the Communications industry's average by over 10%. The company's commitment to innovation is evident in its strategic R&amp;D investments, crucial for maintaining competitive advantage in the rapidly evolving tech landscape. With earnings projected to grow by an impressive annual rate of approximately 36% over the next three years, Ruijie Networks is well-positioned to capitalize on market opportunities and expand its technological offerings further.</p>
<div class="lb-trans"><p>Ruijie Networks 展現出強勁的財務增長，過去一年收入從 117 億人民幣增長至 143 億人民幣，淨收入從 5.74 億人民幣上升至 6.96 億人民幣。這一表現得益於 36.7% 的顯著年盈利增長率，超過了通信行業平均水平 10% 以上。公司對創新的承諾在其戰略研發投資中得以體現，這對在快速發展的科技領域保持競爭優勢至關重要。預計未來三年，Ruijie Networks 的盈利將以約 36% 的年增長率增長，良好的市場機會將進一步推動其技術產品的擴展。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Ruijie Networks.</li>
<li>Assess Ruijie Networks' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此深入瞭解 Ruijie Networks 的完整分析健康報告。</li>
<li>通過我們的詳細歷史表現報告評估 Ruijie Networks 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/a0c69abc-cd2d-4e42-9326-ee1a888b1f87/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:301165 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SZSE:301165 盈利和收入增長</p>
</div><h2>Dexerials (TSE:4980)</h2>
<div class="lb-trans"><h2>Dexerials (TSE:4980)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dexerials Corporation, with a market cap of ¥362.53 billion, specializes in the production and sale of electronic components, bonding materials, and optics materials primarily in Japan.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dexerials Corporation，市值為 3625.3 億日元，專注於電子元件、粘合材料和光學材料的生產和銷售，主要在日本市場。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its Optical Materials and Components segment, which contributes ¥46.62 billion, and the Electronic Materials and Components segment, bringing in ¥64.73 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其光學材料和組件部門產生收入，貢獻了 466.2 億日元，電子材料和組件部門則帶來了 647.3 億日元。</p>
</div><p>Dexerials Corporation, amid a challenging landscape, has managed to maintain steady revenue growth at 8.9% annually. This performance is particularly noteworthy given the slight dip in net income from JPY 23.36 billion to JPY 21.27 billion over the last nine months of reporting, reflecting robust operational resilience. The firm's commitment to innovation is mirrored in its R&amp;D spending which remains a critical aspect of its strategy, aiming to foster advancements and maintain competitiveness in the tech sector where continuous evolution is paramount.</p>
<div class="lb-trans"><p>在充滿挑戰的環境中，Dexerials Corporation 設法保持了 8.9% 的穩定收入增長。考慮到過去九個月淨收入從 233.6 億日元下降至 212.7 億日元，這一表現尤為顯著，反映出強大的運營韌性。公司的創新承諾在其研發支出中得以體現，這仍然是其戰略的關鍵方面，旨在促進技術進步並在持續演變的科技領域保持競爭力。</p>
</div><ul>
<li>Take a closer look at Dexerials' potential here in our health report.</li>
<li>Examine Dexerials' past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 Dexerials 的潛力。</li>
<li>查看 Dexerials 的過去業績報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/95dbf7fd-a146-474e-9a1b-14bf2984e6ca/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4980 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>TSE:4980 截至 2026 年 4 月的收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click here to access our complete index of 199 Global High Growth Tech and AI Stocks.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 199 家全球高增長科技和人工智能股票索引。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新警告信號或風險的提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

High Growth Tech Stocks To Watch In April 2026

- 美股主要指數在中東緊張局勢和能源市場波動中展現韌性。  
- 高增長科技股需具備應對經濟變動的能力和創新潛力。  
- 幾家公司如 Pharming 和 Ruijie Networks 實現了顯著的營收及盈利增長。

2026 年 4 月需要關注的高增長科技股票